NCT01755325暂停3 期
Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Junmin Li13 个研究点 分布在 1 个国家目标入组 680 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 暂停
- 发起方
- 入组人数
- 680
- 试验地点
- 13
- 主要终点
- To compare the rate of Major molecular response（MMR） at 12 months
研究概览
简要总结
It is an open-label, randomized, double blind, placebo-controlled parallel-group, multi-center study to evaluate the efficacy and safety of Compound realgar formula Realgar-Indigo naturalis Tablet combined with Imatinib will be compared with imatinib alone in adult patients with diagnosed Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in the chronic phase (CML-CP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, age >= 18 years and <= 75 years.
- •Eastern Cooperative Oncology Group （ECOG） performance status (PS) score 0, 1, or
- •Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome positive.(Ph+ CML-CP)
- •Ph+ Chronic myelogenous leukemia in chronic phase patients within the first 12 months of diagnosis.
- •Adequate end organ function as defined by:
- •(1). Alanine transaminase（ALT）, Aspartate transaminase（AST） <=2.5 x upper limit of normal（ULN）.
- •(2). Total bilirubin <= 1.5 x ULN. (3).Cr <= 1.5 x ULN. (4). Serum amylase and lipase <= 1.5 x ULN.
- •Signed informed consent.
排除标准
- •Previously received or be receiving any of the following medical treatment for CML:
- •. Treatment with Busulfan within 1 day prior to study entry.
- •. Treatment with interferon-alpha within 2 days prior to study entry.
- •. Treatment with hydroxyurea within 1 day prior to study entry.
- •. Treatment with homoharringtonine within 14 days prior to study entry.
- •. Treatment with Cytosine arabinoside within 28 days prior to study entry.
- •. Surgery (Including hematopoietic stem cell transplantation therapy)
- •. Treatment with anthracyclines, or etoposide within 21 days prior to study entry.
- •Treatment with any tyrosine kinase inhibitor(s) or arsenic reagent prior to study entry
- •Patients who are: (a) pregnant, (b) breast feeding, (c) female or male of childbearing potential unwilling to use contraceptive precautions throughout the trial.
- •Major surgery within 4 weeks prior to randomization or who have not recovered from prior surgery.
- •Patients who have not recovered from toxic reaction of prior similar treatment evaluated by investigators.
- •Impaired cardiac function including any one of the following:
- •LVEF < 45%.
- •. Complete left bundle branch block.
- •. Use of a ventricular-paced pacemaker.
- •. Congenital long QT syndrome.
- •. History or presence of ventricular, clinically significant atrial tachyarrhythmias
- •. History or presence of clinically significant bradyarrhythmia.(heart rate persistently less than 50/min)
- •. QTcF > 450 msec for male or 470 msec for female.
- •. History of clinically documented myocardial infarction or unstable angina (during the last 12 month).
- •.Any other severe heart disease.
- •Patients with active, uncontrolled psychiatric disorders, without insight and the ability of exact expression.
- •Uncontrolled medical conditions:
- •.Uncontrolled diabetes with fasting blood-glucose >200mg/dl (11.1mmol/L),or with combined symptoms (nephropathy, peripheral neuropathy).
- •. Uncontrolled hypertension.
- •. Active or uncontrolled infection (persistent fever and worsening of the clinical symptoms)
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the tested drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).
- •History of chronic pancreatitis or history of acute pancreatitis within 1 year of study entry.
- •Acute or chronic uncontrolled liver disease or severe renal disease considered unrelated to CML.
- •Patients actively receiving therapy with strong CYP3A4 inhibitors, strong CYP3A4 inducers or any medications being potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
- •Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks prior to randomization.
- •Known to be allergic to the study drugs, including crude drug or adjuvant.
- •As investigators evaluate, the patients do not fit to join the study (such as with severe complications) .
研究组 & 干预措施
Compound realgar natural indigo Tablet
Experimental
Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.
imatinib,0.4g,qd
干预措施: Compound realgar natural indigo Tablet (Drug)
placebo
Placebo Comparator
placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.
imatinib 0.4g qd
干预措施: placebo (Drug)
结局指标
主要结局
To compare the rate of Major molecular response（MMR） at 12 months
时间窗: 12 months of follow-up from the start of treatment
次要结局
未报告次要终点
研究者
Junmin Li
Director of hematology department
Ruijin Hospital
研究点 (13)
Loading locations...
相似试验
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorCystic FibrosisNCT02347657Vertex Pharmaceuticals Incorporated510
进行中（未招募）
3 期
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsCarcinoma, Non-Small-Cell LungNCT03706690AstraZeneca407
已完成
3 期
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal WomenHypoactive Sexual Desire DisorderNCT00657501BioSante Pharmaceuticals575
已完成
3 期
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisAtopic DermatitisNCT03796676Pfizer287
已完成
3 期
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose AbnormalitiesCardiovascular Disease, Diabetes Mellitus Type 2NCT01715818Hoffmann-La Roche1,999